Researchers of the University of Silesia have designed new quinoline derivatives that can be used in the treatment of colon and prostate cancer, as well as myeloid leukemia. New compounds and their application have been patented.

New quinoline derivatives have been developed by Dr Eng. Jacek Mularski, Dr Katarzyna Malarz and Prof. Robert Musioł. These compounds are used to modulate the activity of protein kinases – a large group of enzymes responsible for the regulation of a number of metabolic processes and pathways in human and animal cells.

Quinoline derivatives designed in this way can be used in the production of anti-cancer drugs, especially for the treatment of colon and prostate cancer, as well as myeloid leukemia. Compounds can block the activity of kinases and it enables obtaining drugs with high selectivity – the active substances they contain reach the diseased cells without harming healthy cells.